Sunil Suhas Solomon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sunil Suhas Solomon has a total of 288 co-authors. Here are the top co-authors by number of shared publications:
- Allison M. McFall
Department of Epidemiology Johns Hopkins University Bloomberg School of Public Health Baltimore Maryland USA
13 shared publications Shruti H. Mehta
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; and
13 shared publicationsShruti H Mehta
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
11 shared publicationsAylur K. Srikrishnan
YR Gaitonde Centre for AIDS Research and Education, Chennai, India
10 shared publicationsAylur K Srikrishnan
YR Gaitonde Centre for AIDS Research and Education, Chennai, India
9 shared publicationsSanthanam Anand
YR Gaitonde Centre for AIDS Research and Education, Chennai, India
9 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 33 (11) , e70251
Rare and Novel Hepatitis C Virus Genotype Subtypes and Response to Sofosbuvir/Velpatasvir in A5360 ( MINMON ) Clinical Trial
The introduction of potent, well‐tolerated direct‐acting antivirals (DAAs) has transformed hepatitis C virus (HCV) therapy and spurred global elimination efforts. However, the extensive genetic diversity of HCV may affect antiviral efficacy, particularly in low and middle‐income regions where limited data currently exist. Using samples from the ACTG A5360 (MINMON) trial, which evaluated a minimal‐monitoring strategy with 12 weeks of sofosbuvir/velpatasvir (SOF/VEL) across five countries, we characterized rare and novel HCV subtypes and assessed baseline resistance‐associated substitutions (RASs) and treatment response. Genotype/subtype assignments were obtained by NS5B short‐fragment sequencing and confirmed through next‐generation and whole‐genome sequencing. Among 399 participants, 389 (97.5%) were successfully genotyped; whole‐genome sequencing in unresolved genotypes identified several provisional novel genotype 4 subtypes and a putative new genotype 7 subtype (7c). Despite the presence of baseline NS5A RASs, all participants with initially unsubtyped infections achieved sustained virologic response (SVR12). Reduced SVR was observed primarily among genotype 3b infections (78%), consistent with prior data linking A30K + L31M RASs to decreased NS5A inhibitor susceptibility. Overall, SOF/VEL achieved high SVR across genotypes, including rare and novel subtypes. These findings underscore both the increased recognition of global HCV genetic diversity and the robust performance of pangenotypic DAA regimens, supporting universal adoption of simplified treatment strategies, as proposed by the MINMON trial, towards HCV elimination. Trial Registration: ClinicalTrials.gov , NCT03512210.
- 23 October 2026
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 33 (11) , e70251
Open AccessRare and Novel Hepatitis C Virus Genotype Subtypes and Response to Sofosbuvir/Velpatasvir in A5360 ( MINMON ) Clinical Trial
The introduction of potent, well‐tolerated direct‐acting antivirals (DAAs) has transformed hepatitis C virus (HCV) therapy and spurred global elimination efforts. However, the extensive genetic diversity of HCV may affect antiviral efficacy, particularly in low and middle‐income regions where limited data currently exist. Using samples from the ACTG A5360 (MINMON) trial, which evaluated a minimal‐monitoring strategy with 12 weeks of sofosbuvir/velpatasvir (SOF/VEL) across five countries, we characterized rare and novel HCV subtypes and assessed baseline resistance‐associated substitutions (RASs) and treatment response. Genotype/subtype assignments were obtained by NS5B short‐fragment sequencing and confirmed through next‐generation and whole‐genome sequencing. Among 399 participants, 389 (97.5%) were successfully genotyped; whole‐genome sequencing in unresolved genotypes identified several provisional novel genotype 4 subtypes and a putative new genotype 7 subtype (7c). Despite the presence of baseline NS5A RASs, all participants with initially unsubtyped infections achieved sustained virologic response (SVR12). Reduced SVR was observed primarily among genotype 3b infections (78%), consistent with prior data linking A30K + L31M RASs to decreased NS5A inhibitor susceptibility. Overall, SOF/VEL achieved high SVR across genotypes, including rare and novel subtypes. These findings underscore both the increased recognition of global HCV genetic diversity and the robust performance of pangenotypic DAA regimens, supporting universal adoption of simplified treatment strategies, as proposed by the MINMON trial, towards HCV elimination. Trial Registration: ClinicalTrials.gov , NCT03512210.
- Open Access
- 30 June 2026
- Published by Elsevier in Journal of Hepatology
A precision randomized trial of hepatitis C treatment support among people who inject drugs in India: The STOP-C Trial
- 30 June 2026
- Published by Elsevier in Journal of Hepatology
Open AccessA precision randomized trial of hepatitis C treatment support among people who inject drugs in India: The STOP-C Trial
- Open Access
- 1 June 2026
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 101 (6) , 633-642
Increasing Syphilis Prevalence Among MSM Across India Despite Improvements in the HIV Care Continuum
Introduction: Syphilis rates have increased in many regions, especially in men who have sex with men (MSM). Yet data are sparse from low- and middle-income countries. We characterized changes in syphilis prevalence across serial respondent-driven sampling surveys in 10 Indian cities between 2012 and 2024. Methods: We used respondent-driven sampling of MSM in 2012–2013 (10 cities), 2016–2017 (same 10 cities), and 2023–2024 (3 of 10 cities). Participants were ≥18 years, male, and reported sex with a man in the prior 12 months. Participants completed a survey, had a rapid HIV antibody test, with reflex HIV RNA and rapid plasma regain confirmed by Treponema pallidum hemagglutination on stored specimens. We assessed syphilis (rapid plasma regain and Treponema pallidum hemagglutination positive) correlates for the 2016–2017 time period using multilevel Poisson regression models, estimating prevalence ratios. Results: Of 9991, 9993, and 2249 participants, median ages were 25, 29, and 28 years, respectively. Almost 50% reported recent condomless anal sex across all rounds. Syphilis prevalence was 2.9%, 7.4%, 15.6% respectively. Less than 10% of participants with positive serology reported a prior diagnosis of syphilis. During the same period, HIV prevalence and viral load suppression doubled. In multivariable analysis, living with HIV (vs. not), ≥2 recent male sexual partners, self-reported history of syphilis, and recent anogenital ulceration was associated with syphilis. Discussion: Syphilis prevalence dramatically increased among MSM over a decade. Concurrently, HIV viremia substantially declined. These data suggest barriers to syphilis testing in urban Indian MSM. Innovations including dual rapid HIV/syphilis antibody tests may increase detection rates.
- 1 June 2026
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 101 (6) , 633-642
Open AccessIncreasing Syphilis Prevalence Among MSM Across India Despite Improvements in the HIV Care Continuum
Introduction: Syphilis rates have increased in many regions, especially in men who have sex with men (MSM). Yet data are sparse from low- and middle-income countries. We characterized changes in syphilis prevalence across serial respondent-driven sampling surveys in 10 Indian cities between 2012 and 2024. Methods: We used respondent-driven sampling of MSM in 2012–2013 (10 cities), 2016–2017 (same 10 cities), and 2023–2024 (3 of 10 cities). Participants were ≥18 years, male, and reported sex with a man in the prior 12 months. Participants completed a survey, had a rapid HIV antibody test, with reflex HIV RNA and rapid plasma regain confirmed by Treponema pallidum hemagglutination on stored specimens. We assessed syphilis (rapid plasma regain and Treponema pallidum hemagglutination positive) correlates for the 2016–2017 time period using multilevel Poisson regression models, estimating prevalence ratios. Results: Of 9991, 9993, and 2249 participants, median ages were 25, 29, and 28 years, respectively. Almost 50% reported recent condomless anal sex across all rounds. Syphilis prevalence was 2.9%, 7.4%, 15.6% respectively. Less than 10% of participants with positive serology reported a prior diagnosis of syphilis. During the same period, HIV prevalence and viral load suppression doubled. In multivariable analysis, living with HIV (vs. not), ≥2 recent male sexual partners, self-reported history of syphilis, and recent anogenital ulceration was associated with syphilis. Discussion: Syphilis prevalence dramatically increased among MSM over a decade. Concurrently, HIV viremia substantially declined. These data suggest barriers to syphilis testing in urban Indian MSM. Innovations including dual rapid HIV/syphilis antibody tests may increase detection rates.
- 9 January 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (3) , 349-350
When Programs Vanish: The Unseen Consequences
- 9 January 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (3) , 349-350
When Programs Vanish: The Unseen Consequences
- Open Access
- 16 December 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (12) , 2854
teamNGS Balances Sensitivity for Viruses with Comprehensive Microbial Detection in Clinical Specimens
Probe-based capture represents a highly sensitive and cost-effective approach for overcoming host background and enriching viruses in metagenomic NGS (mNGS) libraries. Using clinical specimens collected globally from patients with fever or respiratory illness, we generated mNGS libraries by random priming and Nextera XT tagmentation, followed by target enrichment (teNGS) with Comprehensive Viral Research Panel (CVRP) probes. Capture pool sizes and total reads were optimized, and libraries were initially sequenced separately. Using only 3–4% of reads required for standard mNGS, teNGS achieved increased sensitivity, 100–10,000× increases in depth, and >50% genome coverage for pathogens with titers ≥ 1000 cp/mL. Application to >2000 clinical specimens from various matrices and to contrived samples containing viruses absent from the CVRP probe set enabled detection of diverse viral families and established a minimum 65% nucleotide identity for hybridization, respectively. To save time and resources, teNGS and mNGS libraries were then combined into one sequencing run: teamNGS. In addition to streamlining the workflow, teamNGS also improved genome recovery. Coupling methods maintain the sensitivity and coverage for viruses achieved by enrichment alone while also ensuring comprehensive recovery of non-viral microbes. teamNGS has the potential to improve patient management and lower the rates of unnecessary testing and antibiotic use.
- 16 December 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (12) , 2854
Open AccessteamNGS Balances Sensitivity for Viruses with Comprehensive Microbial Detection in Clinical Specimens
Probe-based capture represents a highly sensitive and cost-effective approach for overcoming host background and enriching viruses in metagenomic NGS (mNGS) libraries. Using clinical specimens collected globally from patients with fever or respiratory illness, we generated mNGS libraries by random priming and Nextera XT tagmentation, followed by target enrichment (teNGS) with Comprehensive Viral Research Panel (CVRP) probes. Capture pool sizes and total reads were optimized, and libraries were initially sequenced separately. Using only 3–4% of reads required for standard mNGS, teNGS achieved increased sensitivity, 100–10,000× increases in depth, and >50% genome coverage for pathogens with titers ≥ 1000 cp/mL. Application to >2000 clinical specimens from various matrices and to contrived samples containing viruses absent from the CVRP probe set enabled detection of diverse viral families and established a minimum 65% nucleotide identity for hybridization, respectively. To save time and resources, teNGS and mNGS libraries were then combined into one sequencing run: teamNGS. In addition to streamlining the workflow, teamNGS also improved genome recovery. Coupling methods maintain the sensitivity and coverage for viruses achieved by enrichment alone while also ensuring comprehensive recovery of non-viral microbes. teamNGS has the potential to improve patient management and lower the rates of unnecessary testing and antibiotic use.
- Open Access
- 1 September 2025
- Published by Wiley in Journal of the International AIDS Society
- Vol. 28 (S5) , e70041
Laser hair removal to antiretrovirals: findings from a person‐centred care model for transgender people in India
Introduction: Transgender women (TGW) in India continue to bear disproportionate HIV burden and face persistent social, legal and structural barriers to receive gender‐affirming care.Methods: Since 2021, we established three “Mitr” (meaning: friend) clinics in Hyderabad, Pune and Thane, India, for transgender people with staffing primarily from the community. Mitr clinics provide free HIV testing and pre‐exposure prophylaxis (PrEP) on site with linkage to government antiretroviral therapy (ART) centres. They also provide free consultation for gender‐affirming hormone therapy (GAHT), subsidized laser hair removal and legal assistance. Client service utilization data were analysed using summary statistics to evaluate uptake of HIV and gender‐affirming services; correlates of HIV testing were examined using logistic regression. Semi‐structured interviews conducted at one site were used to understand barriers/facilitators of HIV testing.Results: A total of 5223 unique clients registered between March 2021 and September 2024; median age was 26 years. Most (86%) self‐identified as TGW, and 35% reported transactional sex. Most clients (70%) had not previously accessed public sector HIV services. The majority (75%) accessed Mitr clinics for gender‐affirming care, including laser hair removal (53%), GAHT consultations (34%) and surgical referral (26%). Over half (62%) of clients eligible for HIV testing underwent screening, of whom 6% were newly diagnosed. Accessing Mitr clinics for gender‐affirming surgical services was significantly associated with HIV testing receipt (aOR: 1.51; 95% CI: 1.02, 2.25). Services provided by staff from the community were a prominent facilitator for HIV testing, while stigma and disclosure concerns were notable barriers. Among 585 clients interested in and eligible for PrEP, 576 (98%) initiated PrEP, and 378 (66%) were PrEP persistent at 3 months. Of 454 clients with HIV (newly diagnosed or previously known), 392 (86%) initiated ART. As of 30 September 2024, 233 (59%) were still receiving Mitr clinic services and retained in HIV care; viral suppression was 98% among the 156 clients with data.Conclusions: The Mitr model highlights the importance of aligning programme and community priorities. The provision of gender‐affirming care attracted many clients who might not otherwise have accessed HIV services; indeed, laser hair removal served as the key entry point to HIV testing, PrEP and ART.
- 1 September 2025
- Published by Wiley in Journal of the International AIDS Society
- Vol. 28 (S5) , e70041
Open AccessLaser hair removal to antiretrovirals: findings from a person‐centred care model for transgender people in India
Introduction: Transgender women (TGW) in India continue to bear disproportionate HIV burden and face persistent social, legal and structural barriers to receive gender‐affirming care.Methods: Since 2021, we established three “Mitr” (meaning: friend) clinics in Hyderabad, Pune and Thane, India, for transgender people with staffing primarily from the community. Mitr clinics provide free HIV testing and pre‐exposure prophylaxis (PrEP) on site with linkage to government antiretroviral therapy (ART) centres. They also provide free consultation for gender‐affirming hormone therapy (GAHT), subsidized laser hair removal and legal assistance. Client service utilization data were analysed using summary statistics to evaluate uptake of HIV and gender‐affirming services; correlates of HIV testing were examined using logistic regression. Semi‐structured interviews conducted at one site were used to understand barriers/facilitators of HIV testing.Results: A total of 5223 unique clients registered between March 2021 and September 2024; median age was 26 years. Most (86%) self‐identified as TGW, and 35% reported transactional sex. Most clients (70%) had not previously accessed public sector HIV services. The majority (75%) accessed Mitr clinics for gender‐affirming care, including laser hair removal (53%), GAHT consultations (34%) and surgical referral (26%). Over half (62%) of clients eligible for HIV testing underwent screening, of whom 6% were newly diagnosed. Accessing Mitr clinics for gender‐affirming surgical services was significantly associated with HIV testing receipt (aOR: 1.51; 95% CI: 1.02, 2.25). Services provided by staff from the community were a prominent facilitator for HIV testing, while stigma and disclosure concerns were notable barriers. Among 585 clients interested in and eligible for PrEP, 576 (98%) initiated PrEP, and 378 (66%) were PrEP persistent at 3 months. Of 454 clients with HIV (newly diagnosed or previously known), 392 (86%) initiated ART. As of 30 September 2024, 233 (59%) were still receiving Mitr clinic services and retained in HIV care; viral suppression was 98% among the 156 clients with data.Conclusions: The Mitr model highlights the importance of aligning programme and community priorities. The provision of gender‐affirming care attracted many clients who might not otherwise have accessed HIV services; indeed, laser hair removal served as the key entry point to HIV testing, PrEP and ART.
- Open Access
- 21 April 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (5)
Health economic outcomes of a minimal monitoring approach to providing HCV therapy
Background: The ACTG A5360 trial demonstrated that HCV treatment without planned on-treatment monitoring is safe and effective. We report the health economic outcomes of MINMON. Methods: A5360 was a 5-country, single-arm trial providing sofosbuvir/velpatasvir to people with HCV infection with no planned clinic visits between treatment initiation and week 24 sustained virologic response (SVR) evaluation. Trial records included planned/and most unplanned lab tests and visits. Participants completed a 4-week recall questionnaire at weeks 0, 24, 48, and 72 reporting hospital nights, emergency department visits, and ambulatory visits. We tabulated consumption and multiplied units of consumption by country-specific cost. We report the cost and cost per SVR of MINMON (2020 US$) from program and health sector perspectives. Sensitivity analyses compared MINMON costs to the standard of care (SoC). We consulted in-country experts to develop country-specific SoC treatment protocols and used micro-costing to estimate their costs. We compare the cost/SVR in MINMON with that of the simulated SoC, varying the expected SVR with the SoC. Results: MINMON cost/SVR (program perspective) varied by country from $1692/SVR (Thailand) to $27,632/SVR (United States). The cost/SVR (health sector perspective) ranged from $6273/SVR (South Africa) to $123,974/SVR (United States) MINMON had a lower cost/SVR than SoC across broad assumptions about SVR proportions, especially in low- and middle-income countries. In the United States-, MINMON had an appealing cost per cure compared to the SoC, unless retention on treatment fell below the SoC. Conclusions: MINMON is a cost-saving strategy for HCV treatment, particularly in low- and middle-income country settings.
- 21 April 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (5)
Open AccessHealth economic outcomes of a minimal monitoring approach to providing HCV therapy
Background: The ACTG A5360 trial demonstrated that HCV treatment without planned on-treatment monitoring is safe and effective. We report the health economic outcomes of MINMON. Methods: A5360 was a 5-country, single-arm trial providing sofosbuvir/velpatasvir to people with HCV infection with no planned clinic visits between treatment initiation and week 24 sustained virologic response (SVR) evaluation. Trial records included planned/and most unplanned lab tests and visits. Participants completed a 4-week recall questionnaire at weeks 0, 24, 48, and 72 reporting hospital nights, emergency department visits, and ambulatory visits. We tabulated consumption and multiplied units of consumption by country-specific cost. We report the cost and cost per SVR of MINMON (2020 US$) from program and health sector perspectives. Sensitivity analyses compared MINMON costs to the standard of care (SoC). We consulted in-country experts to develop country-specific SoC treatment protocols and used micro-costing to estimate their costs. We compare the cost/SVR in MINMON with that of the simulated SoC, varying the expected SVR with the SoC. Results: MINMON cost/SVR (program perspective) varied by country from $1692/SVR (Thailand) to $27,632/SVR (United States). The cost/SVR (health sector perspective) ranged from $6273/SVR (South Africa) to $123,974/SVR (United States) MINMON had a lower cost/SVR than SoC across broad assumptions about SVR proportions, especially in low- and middle-income countries. In the United States-, MINMON had an appealing cost per cure compared to the SoC, unless retention on treatment fell below the SoC. Conclusions: MINMON is a cost-saving strategy for HCV treatment, particularly in low- and middle-income country settings.
- 28 February 2025
- Published by Springer Nature in Quality of Life Research
- Vol. 34 (6) , 1683-1694
Impact of a minimal monitoring HCV treatment approach on Health-Related Quality of Life
Background Direct-acting antivirals (DAA) are highly effective for the management of HCV disease. This study aims to evaluate changes in health-related quality of life (HQoL) among people with HCV who were treated with DAAs using a minimal monitoring (MINMON) approach. Methods ACTG A5360 was a multicenter, international (Brazil, South Africa, Thailand, Uganda, and USA) trial to assess the feasibility and efficacy of MINMON approach in people with HCV. We measured HQoL using EQ-5D-3L at baseline, sustained virological evaluation visit, week 48 and week 72, and described using EQ-5D summary index (ranges:0-1) and visual analog scale (VAS) score (ranges 0-100). We used paired T-tests to evaluate the change in EQ-5D summary and multivariable linear regression for changes in VAS scores. Results Overall, 394 individuals were included; most did not have cirrhosis (360; 91%) or problematic alcohol use (278; 71%). We found HQoL improvements for participants from Brazil and Thailand, but not for the USA. Participants reported high rates of pain/discomfort and anxiety/depression, with decreases over time only for Brazil. Factors associated with larger improvements in VAS scores included: cirrhosis at baseline, and non-use or problematic use of other substances (apart from tobacco/marijuana) compared to non-problematic use. Conclusion We found HQoL improvements among people with HCV following DAA treatment with variability across countries. Our findings reinforce the importance of DAA treatment, especially among those with advanced HCV disease. Continuous mental health care including depression and substance use support should be offered to individuals after HCV treatment. Trial Registration Number NCT03512210 (22-Oct-2018) Plain English Summary Direct-acting antivirals are highly effective for the management of hepatitis C disease. Recent studies have shown that hepatitis C treatment with direct-acting antivirals has a positive impact on quality of life. However, no studies have assessed quality of life among individuals starting direct-acting antivirals treatment across multiple countries representing high-, middle- and low-income settings. In this study, we evaluated changes in health-related quality of life among people with hepatitis C who were treated with direct-acting antivirals using a simplified treatment delivery and offering minimal in-person monitoring. We found quality of life improvements among persons with hepatitis C after direct-acting antivirals treatment, with differences across countries. Although direct-acting antivirals treatment works well and should be available to all persons with hepatitis C, we found that participants with cirrhosis (liver damage) had higher improvements in quality of life, reinforcing the importance of starting treatment among people with advanced hepatitis C. We also found high rates of anxiety and depression, pointing to the importance of adding mental health care and support to infectious diseases services.
- 28 February 2025
- Published by Springer Nature in Quality of Life Research
- Vol. 34 (6) , 1683-1694
Impact of a minimal monitoring HCV treatment approach on Health-Related Quality of Life
Background Direct-acting antivirals (DAA) are highly effective for the management of HCV disease. This study aims to evaluate changes in health-related quality of life (HQoL) among people with HCV who were treated with DAAs using a minimal monitoring (MINMON) approach. Methods ACTG A5360 was a multicenter, international (Brazil, South Africa, Thailand, Uganda, and USA) trial to assess the feasibility and efficacy of MINMON approach in people with HCV. We measured HQoL using EQ-5D-3L at baseline, sustained virological evaluation visit, week 48 and week 72, and described using EQ-5D summary index (ranges:0-1) and visual analog scale (VAS) score (ranges 0-100). We used paired T-tests to evaluate the change in EQ-5D summary and multivariable linear regression for changes in VAS scores. Results Overall, 394 individuals were included; most did not have cirrhosis (360; 91%) or problematic alcohol use (278; 71%). We found HQoL improvements for participants from Brazil and Thailand, but not for the USA. Participants reported high rates of pain/discomfort and anxiety/depression, with decreases over time only for Brazil. Factors associated with larger improvements in VAS scores included: cirrhosis at baseline, and non-use or problematic use of other substances (apart from tobacco/marijuana) compared to non-problematic use. Conclusion We found HQoL improvements among people with HCV following DAA treatment with variability across countries. Our findings reinforce the importance of DAA treatment, especially among those with advanced HCV disease. Continuous mental health care including depression and substance use support should be offered to individuals after HCV treatment. Trial Registration Number NCT03512210 (22-Oct-2018) Plain English Summary Direct-acting antivirals are highly effective for the management of hepatitis C disease. Recent studies have shown that hepatitis C treatment with direct-acting antivirals has a positive impact on quality of life. However, no studies have assessed quality of life among individuals starting direct-acting antivirals treatment across multiple countries representing high-, middle- and low-income settings. In this study, we evaluated changes in health-related quality of life among people with hepatitis C who were treated with direct-acting antivirals using a simplified treatment delivery and offering minimal in-person monitoring. We found quality of life improvements among persons with hepatitis C after direct-acting antivirals treatment, with differences across countries. Although direct-acting antivirals treatment works well and should be available to all persons with hepatitis C, we found that participants with cirrhosis (liver damage) had higher improvements in quality of life, reinforcing the importance of starting treatment among people with advanced hepatitis C. We also found high rates of anxiety and depression, pointing to the importance of adding mental health care and support to infectious diseases services.
- Open Access
- 15 November 2024
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 32 (4)
Preferences and Feasibility of Long‐Acting Technologies for the Treatment of Hepatitis C Virus: A Survey of Patients in Diverse Low‐ and Middle‐Income Countries
Despite available curative treatments, global rates of hepatitis C virus (HCV) infection persist with significant burden in low‐ and middle‐income countries (LMICs). Long‐acting (LA) antiviral products are in development. This study explored the challenges and opportunities in LA‐HCV treatment across three LMICs: Egypt, Ethiopia and India. The survey focused on understanding barriers and facilitators to treatment, with emphasis on LA treatment preferences. Four‐hundred respondents completed a survey including demographics, HCV treatment history and preferences for injections, implants and microarray patches (MAPs) compared to pills. Overall, 78% of respondents were willing to receive injections, 43% were willing to receive implants and 55% were willing to receive MAPs. Marked heterogeneity in acceptability of non‐oral treatments was observed. Among respondents who had not previously received HCV treatment, 94%, 43%, and 75% were willing to receive injections, implants, or MAPs, respectively. In contrast, among those already cured by oral HCV treatment, 61%, 40% and 43% were willing to receive injections, implants or MAPs. Other characteristics associated with willingness to receive an injection included urban residence, younger age, male sex, higher education level and taking pills for any reason (all results p < 0.001). The most common concern for all LA modalities was lack of effectiveness. Prior experience with injection or implant increased willingness to receive any LA modality (p < 0.001). Coupled with a point‐of‐care HCV diagnostic test, availability of and willingness to receive HCV treatment delivered by a LA formulation could simplify and expand treatment access in LMICs and contribute towards global HCV elimination goals.
- 15 November 2024
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 32 (4)
Open AccessPreferences and Feasibility of Long‐Acting Technologies for the Treatment of Hepatitis C Virus: A Survey of Patients in Diverse Low‐ and Middle‐Income Countries
Despite available curative treatments, global rates of hepatitis C virus (HCV) infection persist with significant burden in low‐ and middle‐income countries (LMICs). Long‐acting (LA) antiviral products are in development. This study explored the challenges and opportunities in LA‐HCV treatment across three LMICs: Egypt, Ethiopia and India. The survey focused on understanding barriers and facilitators to treatment, with emphasis on LA treatment preferences. Four‐hundred respondents completed a survey including demographics, HCV treatment history and preferences for injections, implants and microarray patches (MAPs) compared to pills. Overall, 78% of respondents were willing to receive injections, 43% were willing to receive implants and 55% were willing to receive MAPs. Marked heterogeneity in acceptability of non‐oral treatments was observed. Among respondents who had not previously received HCV treatment, 94%, 43%, and 75% were willing to receive injections, implants, or MAPs, respectively. In contrast, among those already cured by oral HCV treatment, 61%, 40% and 43% were willing to receive injections, implants or MAPs. Other characteristics associated with willingness to receive an injection included urban residence, younger age, male sex, higher education level and taking pills for any reason (all results p < 0.001). The most common concern for all LA modalities was lack of effectiveness. Prior experience with injection or implant increased willingness to receive any LA modality (p < 0.001). Coupled with a point‐of‐care HCV diagnostic test, availability of and willingness to receive HCV treatment delivered by a LA formulation could simplify and expand treatment access in LMICs and contribute towards global HCV elimination goals.
- Open Access
Family-centred interventions for people with substance use disorders in low-income and middle-income country settings: a scoping review protocol
Introduction Substance use disorder (SUD) and problematic substance use are global public health concerns with significant multifaceted implications for physical health and psychosocial well-being. The impact of SUD extends beyond the individual to their family while imposing financial and social burdens on the community. Though family-centred interventions have shown promise in addressing SUD, their implementation and impact in low-income and middle-income countries (LMICs) remain underexplored. Methods and analysis Per Joanna Briggs Institute’s scoping review protocol, a systematic search strategy was employed across OVID Medline, Embase, PsycINFO, Web of Science–Core Collection, Global Health and CINAHL from 22 February 2024 to 26 February 2024, to identify relevant studies focused on family-centred interventions for SUD in LMIC, devoid of publication time and language constraints. Two independent reviewers will screen the titles, abstracts and full texts, with discrepancies resolved through discussion or third-party reviews. The extracted data charted in a structured form will be visualised by diagrams or tables, focusing on the feasibility and impact of family-centred interventions for SUD in LMIC. For qualitative studies, the findings will be synthesised and presented in thematic clusters, and for studies that report quantitative outcomes, specific health, including SUD and psychosocial, outcomes will be synthesised, aligning with the Population, Concept and Context framework. Ethics and dissemination These data on substance use, psychosocial outcomes and perspectives of individuals with SUD and their families will be presented in narrative format, highlighting patterns and identifying research gaps. This review aims to synthesise the existing evidence on family-centred interventions for improving substance use and/or psychosocial outcomes in individuals with SUD in LMIC and seeks to inform future policy and practice. Ethics approval is not required for this scoping review, and modifications to the review protocol will be disclosed. Findings will be disseminated through conference proceedings and peer-reviewed publication.
Open AccessFamily-centred interventions for people with substance use disorders in low-income and middle-income country settings: a scoping review protocol
Introduction Substance use disorder (SUD) and problematic substance use are global public health concerns with significant multifaceted implications for physical health and psychosocial well-being. The impact of SUD extends beyond the individual to their family while imposing financial and social burdens on the community. Though family-centred interventions have shown promise in addressing SUD, their implementation and impact in low-income and middle-income countries (LMICs) remain underexplored. Methods and analysis Per Joanna Briggs Institute’s scoping review protocol, a systematic search strategy was employed across OVID Medline, Embase, PsycINFO, Web of Science–Core Collection, Global Health and CINAHL from 22 February 2024 to 26 February 2024, to identify relevant studies focused on family-centred interventions for SUD in LMIC, devoid of publication time and language constraints. Two independent reviewers will screen the titles, abstracts and full texts, with discrepancies resolved through discussion or third-party reviews. The extracted data charted in a structured form will be visualised by diagrams or tables, focusing on the feasibility and impact of family-centred interventions for SUD in LMIC. For qualitative studies, the findings will be synthesised and presented in thematic clusters, and for studies that report quantitative outcomes, specific health, including SUD and psychosocial, outcomes will be synthesised, aligning with the Population, Concept and Context framework. Ethics and dissemination These data on substance use, psychosocial outcomes and perspectives of individuals with SUD and their families will be presented in narrative format, highlighting patterns and identifying research gaps. This review aims to synthesise the existing evidence on family-centred interventions for improving substance use and/or psychosocial outcomes in individuals with SUD in LMIC and seeks to inform future policy and practice. Ethics approval is not required for this scoping review, and modifications to the review protocol will be disclosed. Findings will be disseminated through conference proceedings and peer-reviewed publication.